• Male or female subjects ≥ 18 years of age

• Histologic or cytologic evidence of NSCLC

• Known KRAS G12C mutation

• The subject must have received prior therapy with a KRAS G12C inhibitor and experienced progression

• Must have received appropriate treatment with at least one prior systemic regimen, but no more than 3 prior regimens, for Stage 3B-C or 4 NSCLC

• Measurable disease according to RECIST 1.1

• An Eastern Cooperative Group (ECOG) performance status ≤ 1

• Adequate organ function

• Adequate recovery from toxicities related to prior treatments

• Agreement to use highly effective method of contraceptive